The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen

British Journal of Pharmacology
A G Blakeley, R J Summers


1. The competitive alpha- and beta-adrenoceptor blocking agent labetalol, in concentrations up to 10(-4) M, produced dose-dependent increases in transmitter overflow from the isolated blood perfused spleen of the cat following nerve stimulation at 10 and 30 Hz. 2. At concentrations above 10(-4) M labetol produced a pronounced decrease in transmitter overflow. 3. Labetalol (1.5 X 10(-4) M) increased the recovery of 3H label in the venous blood following the close-arterial infusion of [3H]-(-)-noradrenaline indicating that the drug inhibits uptake of the amine. 4. Both labetalol (3.8 X 10(-5) M) and piperoxan (7.4 X 10(-6) M) produced parallel shifts to the right of the dose-response curves to noradrenaline and oxymetazoline in isolated strips of cat splenic capsule. In this preparation both drugs acted as competitive postsynaptic alpha-adrenoceptor blocking agents. 5. Labetalol (3.3 X 10(-5) M) increased the transmitter overflow following stimulation of the splenic nerves with 200 impulses at 10 Hz. The overflow could be further increased by subsequent addition of piperoxan (7.2 X 10(-6 M). Piperoxan (5.7 X 10(-6) M) alone produced a marked increase in transmitter overflow which could be further increased by subsequent addition ...Continue Reading


Nov 3, 1975·Naunyn-Schmiedeberg's Archives of Pharmacology·K StarkeH D Taube
Apr 1, 1972·British Journal of Pharmacology·M A EneroF J Stefano
Apr 1, 1973·British Journal of Pharmacology·A G BlakeleyR J Summers
Dec 23, 1969·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·A G BlakeleyR I Woods
Nov 1, 1970·British Journal of Pharmacology·A M Barrett, J Carter
Feb 1, 1972·The Journal of Pharmacy and Pharmacology·J HäggendalB Ljung
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·K Starke
Aug 1, 1972·British Journal of Pharmacology·J B FarmerR J Marshall
Jul 1, 1974·Biochemical Pharmacology·S Z Langer
Dec 1, 1973·British Journal of Pharmacology·J Hughes
Feb 10, 1967·Annals of the New York Academy of Sciences·E J Ariëns
May 1, 1970·British Journal of Pharmacology·W J Davidson, I R Innes
Aug 1, 1970·British Journal of Pharmacology·A T BirminghamJ Wójcicki
Aug 29, 1957·The Journal of Physiology·G L BROWN, J S GILLESPIE
Jul 1, 1963·The Journal of Physiology·A G BLAKELEYC B FERRY
Apr 1, 1947·Proceedings of the Society for Experimental Biology and Medicine·R E SHIPLEY, J H TILDEN

❮ Previous
Next ❯


Nov 1, 1978·Naunyn-Schmiedeberg's Archives of Pharmacology·S A Doggrell, D M Paton
Jan 1, 1983·Pharmacology & Therapeutics·A J Scriven, P J Lewis
Jan 1, 1978·General Pharmacology·A G Blakeley, R J Summers
Jan 1, 1997·Pharmacology & Therapeutics·S M KhedunB Maharaj
Jun 1, 1978·British Journal of Clinical Pharmacology·D A RichardsB N Prichard
Apr 1, 1979·British Journal of Clinical Pharmacology·D A RichardsR Hernández
Jan 1, 1982·Clinical and Experimental Pharmacology & Physiology·G A McPherson, R J Summers
Apr 1, 1979·British Journal of Pharmacology·R J Summers, J Tillman
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·M L Cohen, L M Hynes
Jul 1, 1978·The Journal of Pharmacy and Pharmacology·S A Doggrell, D M Paton
Aug 1, 1984·The Journal of Pharmacy and Pharmacology·T TakenakaN Inukai
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·K E Andersson
Apr 1, 1979·British Journal of Clinical Pharmacology·L Kaufman
Apr 1, 1979·British Journal of Clinical Pharmacology·B N Prichard, D A Richards
Jan 1, 1979·Pharmacological Research Communications·H Kapur, D R Mottram

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.